Focused On-demand Library for Interphotoreceptor matrix proteoglycan 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9BZV3

UPID:

IMPG2_HUMAN

Alternative names:

Interphotoreceptor matrix proteoglycan of 200 kDa; Sialoprotein associated with cones and rods proteoglycan

Alternative UPACC:

Q9BZV3; A8MWT5; Q9UKD4; Q9UKK5

Background:

Interphotoreceptor matrix proteoglycan 2, also known as a 200 kDa sialoprotein associated with cones and rods, plays a crucial role in the organization of the interphotoreceptor matrix. It binds to chondroitin sulfate and hyaluronan, contributing to the maturation and maintenance of photoreceptor outer segments. This protein's interaction with heparin highlights its significance in the retinal structure.

Therapeutic significance:

Given its involvement in Retinitis pigmentosa 56 and Macular dystrophy, vitelliform, 5, understanding the role of Interphotoreceptor matrix proteoglycan 2 could open doors to potential therapeutic strategies. These diseases, characterized by loss of vision and retinal degeneration, underscore the protein's clinical relevance.